1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > PharmaPoint: Irritable Bowel Syndrome - US Drug Forecast and Market Analysis to 2023

PharmaPoint: Irritable Bowel Syndrome - US Drug Forecast and Market Analysis to 2023

  • December 2014
  • -
  • GlobalData
  • -
  • 116 pages

Summary

Table of Contents

Search Inside

PharmaPoint: Irritable Bowel Syndrome - US Drug Forecast and Market Analysis to 2023

Summary

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

GlobalData estimated that prescription drug sales for IBS in the US were approximately $480.1m in 2013. The key growth drivers for the IBS market in the US are the anticipated increasing uptake of Ironwood/Actavis/Almirall/Astellas’ Linzess, the potential label expansion of Salix/Alfa Wassermann/Norgine/Bama-Geve’s Xifaxan for IBS-D, the potential introduction of four additional therapies, and the increasing prevalent cases of IBS during the forecast period.

Scope

- Overview of Irritable Bowel Syndrome including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Irritable Bowel Syndrome market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Irritable Bowel Syndrome
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in the US

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Irritable Bowel Syndrome Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Irritable Bowel Syndrome Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Irritable Bowel Syndrome in 12 Major Markets Irritable Bowel Syndrome (IBS) is a functional bowel disorder which incorporates a group ...

Gastroesophageal Reflux Disease (GERD)  - Market Insights, Epidemiology and Market Forecast-2023

Gastroesophageal Reflux Disease (GERD)  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s Gastroesophageal Reflux Disease (GERD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Gastroesophageal ...

Irritable Bowel Syndrome - Market Insights, Epidemiology and Market Forecast-2023

Irritable Bowel Syndrome - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • March 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Irritable Bowel Syndrome - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


Download Unlimited Documents from Trusted Public Sources

Gastrointestinal Drug Industry in Canada

  • March 2017
    92 pages
  • Gastrointestina...  

    Health Care Pro...  

    Ambulatory Care  

  • Canada  

    North America  

View report >

Gastrointestinal Drug Industry in Canada

  • March 2017
    92 pages
  • Gastrointestina...  

    Health Care Pro...  

    Ambulatory Care  

  • Canada  

    North America  

View report >

Gastrointestinal Drug Industry in the US - Forecast

  • January 2017
    4 pages
  • Gastrointestina...  

    Digestive Syste...  

    Hormone  

  • United States  

View report >

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.